Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.37 |
| ▸ | CTSD | P07339 | 4/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777045 | 0.85 | NPSR1 (0.30) | — | |
| SCHEMBL3359520 | 0.85 | BACE1 (0.36) | BACE1CTSDRXFP1KCNH2EGFR | |
| SCHEMBL3635544 | 0.84 | BACE1 (0.53) | BACE1CTSDKCNH2BACE2NPC1 | |
| SCHEMBL3638143 | 0.83 | BACE1 (0.51) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL3243724 | 0.83 | KDM1A (0.40) | BACE1CTSDKCNH2BACE2KDM1A | |
| SCHEMBL3640268 | 0.82 | BACE1 (0.58) | BACE1CTSDBACE2 | |
| SCHEMBL3635663 | 0.82 | BACE1 (0.45) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL3359617 | 0.81 | CHRNA1 (0.32) | — | |
| SCHEMBL3359177 | 0.79 | BACE1 (0.35) | BACE1KCNH2BACE2 | |
| SCHEMBL3360854 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-7629356-B2 | Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions | ASTRAZENECA AB (SE) | 2009-12-08 | — | — | US | disclosed |
| US-7629356-B2 | Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions | ASTRAZENECA AB (SE) | 2009-12-08 | — | — | US | disclosed |
| US-7629356-B2 | Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions | ASTRAZENECA AB (SE) | 2009-12-08 | — | — | US | disclosed |
| US-20090233945-A9 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233945-A9 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233945-A9 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| WO-2009022961-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
| US-20080287462-A1 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287462-A1 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287462-A1 | NEW COMPOUNDS 834 | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324072-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 44/4885RXFP1 4653/4885 |
| US-20090233945-A9 | NEW COMPOUNDS 834 | MAPT, PSEN1, PSEN2 | BACE1 4/4885CTSD 1386/4885RXFP1 3441/4885 |
| US-20080287462-A1 | NEW COMPOUNDS 834 | MAPT, PSEN1, PSEN2 | BACE1 4/4885CTSD 1386/4885RXFP1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.